Abstract

Part I of this article, which appeared in the previous issue of the Journal, reviewed calcineurin inhibitors —ciclosporin and tacrolimus. In part II, we review the pharmacokinetics and therapeutic drug monitoring of mycophenolate and mammalian target of rapamycin inhibitors — sirolimus and everolimus — in thoracic transplantation, and we provide an overall discussion and suggest various areas for future study.